Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
1.
Clin Infect Dis ; 74(12): 2129-2135, 2022 07 06.
Artigo em Inglês | MEDLINE | ID: mdl-34555149

RESUMO

BACKGROUND: Vulvovaginal candidiasis affects approximately 75% of women in their lifetime. Approved treatment options are limited to oral or topical azoles. Ibrexafungerp, a novel, first-in-class oral triterpenoid glucan synthase inhibitor, has demonstrated broad fungicidal Candida activity and a favorable tolerability profile. The primary objective of this dose-finding study was to identify the optimal dose of oral ibrexafungerp in patients with acute vulvovaginal candidiasis. METHODS: Patients with vulvovaginal signs and symptoms score ≥7 were randomized equally to 6 treatments groups: 5 treatment doses of oral ibrexafungerp or oral fluconazole 150 mg. The primary endpoint was the percentage of patients with a clinical cure (complete resolution of vulvovaginal signs and symptoms) at the test-of-cure visit (day 10). RESULTS: Overall, 186 patients were randomized into the 6 treatment groups. Results, using the modified intent-to-treat population (baseline positive culture), are reported for ibrexafungerp 300 mg twice daily (BID) for 1 day (n = 27), which was the dose selected for phase 3 studies, and fluconazole 150 mg for 1 day (n = 24). At day 10, the clinical cure rates for ibrexafungerp and fluconazole were 51.9% and 58.3%, respectively; at day 25, patients with no signs or symptoms were 70.4% and 50.0%, respectively. During the study ibrexafungerp patients required less antifungal rescue medications compared with fluconazole (3.7% vs 29.2%, respectively). Ibrexafungerp was well tolerated, with the most common treatment-related adverse events being mild gastrointestinal events. CONCLUSIONS: Ibrexafungerp is a well-tolerated novel antifungal with comparable efficacy to fluconazole in the treatment of acute vulvovaginal candidiasis. CLINICAL TRIALS REGISTRATION: NCT03253094.


Assuntos
Candidíase Vulvovaginal , Triterpenos , Administração Oral , Antifúngicos/efeitos adversos , Candidíase Vulvovaginal/tratamento farmacológico , Feminino , Fluconazol/efeitos adversos , Glicosídeos , Humanos , Triterpenos/efeitos adversos
2.
Clin Infect Dis ; 74(11): 1979-1985, 2022 06 10.
Artigo em Inglês | MEDLINE | ID: mdl-34467969

RESUMO

BACKGROUND: Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azole therapy. Ibrexafungerp is a first-in-class triterpenoid antifungal with broad-spectrum anti-Candida fungicidal activity. The objective of this study was to evaluate the efficacy and safety of ibrexafungerp compared with placebo in patients with acute VVC. METHODS: Patients were randomly assigned 2:1 to receive ibrexafungerp (300 mg twice for 1 day) or placebo. The primary endpoint was the percentage of patients with a clinical cure (complete resolution of vulvovaginal signs and symptoms [VSS] = 0) at test-of-cure (day 11 ± 3). Secondary endpoints included the percentage of patients with mycological eradication, overall success (clinical cure and mycological eradication), clinical improvement (VSS ≤ 1) at test-of-cure, and symptom resolution at follow-up (day 25 ± 4). RESULTS: Patients receiving ibrexafungerp had significantly higher rates of clinical cure (50.5% [95/188] vs 28.6% [28/98]; P = .001), mycological eradication (49.5% [93/188] vs 19.4% [19/98]; P < .001), and overall success (36.0% [64/178] vs 12.6% [12/95]; P < .001) compared with placebo. Symptom resolution was sustained and further increased with ibrexafungerp compared with placebo (59.6% [112/188] vs 44.9% [44/98]; P = .009) at follow-up. Post hoc analysis showed similar rates of clinical cure and clinical improvement at test-of-cure for Black patients (54.8% [40/73] and 63.4% [47/73], respectively) and patients with a body mass index >35 (54.5% [24/44] and 68.2% [30/44], respectively) compared with overall rates. Ibrexafungerp was well tolerated. Adverse events were primarily gastrointestinal and mild in severity. CONCLUSIONS: Ibrexafungerp provides a promising safe and efficacious oral treatment that mechanistically differs from current azole treatment options for acute VVC.


Assuntos
Candidíase Vulvovaginal , Triterpenos , Antifúngicos/efeitos adversos , Azóis/uso terapêutico , Candidíase Vulvovaginal/tratamento farmacológico , Feminino , Glicosídeos/uso terapêutico , Humanos , Triterpenos/efeitos adversos
3.
Antimicrob Agents Chemother ; 65(8): e0056221, 2021 07 16.
Artigo em Inglês | MEDLINE | ID: mdl-34001513

RESUMO

The vaginal environment with candidiasis has a pH of 3.8 to 4.5 and this has a negative effect on the activity of antifungals. Ibrexafungerp was evaluated against 187 Candida isolates, including fluconazole-sensitive and -resistant Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis with the media adjusted to pH 7.0 and pH 4.5. Ibrexafungerp MIC values were not adversely affected when tested at pH 4.5. Ibrexafungerp exhibited significant activity against all isolates at pH 4.5.


Assuntos
Candidíase Vulvovaginal , Fluconazol , Antifúngicos/farmacologia , Antifúngicos/uso terapêutico , Candida , Candidíase Vulvovaginal/tratamento farmacológico , Farmacorresistência Fúngica , Feminino , Fluconazol/farmacologia , Glicosídeos , Humanos , Concentração de Íons de Hidrogênio , Testes de Sensibilidade Microbiana , Pichia , Triterpenos
4.
Artigo em Inglês | MEDLINE | ID: mdl-32179521

RESUMO

Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1→3)-ß-d-glucan synthase inhibitor. We investigated the in vitro activity, pharmacokinetics, and in vivo efficacy of ibrexafungerp (SCY) alone and in combination with antimold triazole isavuconazole (ISA) against invasive pulmonary aspergillosis (IPA). The combination of ibrexafungerp and isavuconazole in in vitro studies resulted in additive and synergistic interactions against Aspergillus spp. Plasma concentration-time curves of ibrexafungerp were compatible with linear dose proportional profile. In vivo efficacy was studied in a well-established persistently neutropenic New Zealand White (NZW) rabbit model of experimental IPA. Treatment groups included untreated control (UC) rabbits and rabbits receiving ibrexafungerp at 2.5 (SCY2.5) and 7.5 (SCY7.5) mg/kg of body weight/day, isavuconazole at 40 (ISA40) mg/kg/day, or combinations of SCY2.5+ISA40 and SCY7.5+ISA40. The combination of SCY+ISA produced an in vitro synergistic interaction. There were significant in vivo reductions of residual fungal burden, lung weights, and pulmonary infarct scores in SCY2.5+ISA40, SCY7.5+ISA40, and ISA40 treatment groups versus those of the SCY2.5-treated, SCY7.5-treated, and UC (P < 0.01) groups. Rabbits treated with SCY2.5+ISA40 and SCY7.5+ISA40 had prolonged survival in comparison to that of the SCY2.5-, SCY7.5-, ISA40-treated, or UC (P < 0.05) groups. Serum galactomannan index (GMI) and (1→3)-ß-d-glucan levels significantly declined in animals treated with the combination of SCY7.5+ISA40 in comparison to those of animals treated with SCY7.5 or ISA40 (P < 0.05). Ibrexafungerp and isavuconazole combination demonstrated prolonged survival, decreased pulmonary injury, reduced residual fungal burden, and lower GMI and (1→3)-ß-d-glucan levels in comparison to those of single therapy for treatment of IPA. These findings provide an experimental foundation for clinical evaluation of the combination of ibrexafungerp and an antimold triazole for treatment of IPA.


Assuntos
Aspergilose Pulmonar Invasiva , Triterpenos , Animais , Antifúngicos/uso terapêutico , Glucanos , Glicosídeos , Aspergilose Pulmonar Invasiva/tratamento farmacológico , Nitrilas , Piridinas , Coelhos , Triazóis
5.
Mycoses ; 61(5): 331-336, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29364548

RESUMO

Neutropenia is linked to the development of invasive candidiasis/candidaemia, for which micafungin has demonstrated efficacy, but evidence in patients with neutropenia is limited. The aim of this study was to evaluate the efficacy of micafungin for the treatment of invasive candidiasis/candidaemia in patients with neutropenia (<500 neutrophils/µL) and without neutropenia. This pooled, post hoc analysis of 2 Phase 3 trials compared micafungin 100 mg/d (adults) and 2 mg/kg/d (paediatrics) with L-AmB 3 mg/kg/d (NCT00106288) and micafungin 100 mg/d and 150 mg/d with caspofungin 70 mg/d followed by 50 mg/d (adults) (NCT00105144); treatment duration 2-4 weeks (≤8 weeks for chronic disseminated candidiasis). Effects of neutropenia duration and Candida spp. on efficacy outcomes (treatment success, clinical and mycological response) were examined. Of 685 patients, 77 had neutropenia. The most common infection in patients with/without neutropenia was due to C. tropicalis (31/77) and C. albicans (295/608) respectively. Overall success was numerically lower in patients with vs without neutropenia (63.6% vs 72.9%). Clinical and mycological response was similar between groups. Neutropenia duration or Candida spp. did not impact micafungin's overall success rate. This analysis supports evidence that micafungin is effective against invasive candidiasis/candidaemia in patients with neutropenia, irrespective of neutropenia duration or Candida spp., although overall success may be lower than in patients without neutropenia.


Assuntos
Antifúngicos/uso terapêutico , Candidemia/tratamento farmacológico , Candidíase Invasiva/tratamento farmacológico , Equinocandinas/uso terapêutico , Lipopeptídeos/uso terapêutico , Neutropenia/microbiologia , Adolescente , Adulto , Antifúngicos/administração & dosagem , Candida/efeitos dos fármacos , Candida albicans/efeitos dos fármacos , Candida albicans/isolamento & purificação , Candida tropicalis/efeitos dos fármacos , Candida tropicalis/isolamento & purificação , Candidemia/complicações , Candidemia/microbiologia , Candidíase/complicações , Candidíase/tratamento farmacológico , Candidíase/microbiologia , Candidíase Invasiva/complicações , Candidíase Invasiva/microbiologia , Caspofungina , Equinocandinas/administração & dosagem , Equinocandinas/efeitos adversos , Feminino , Humanos , Lipopeptídeos/administração & dosagem , Lipopeptídeos/efeitos adversos , Masculino , Micafungina , Pessoa de Meia-Idade , Neutropenia/complicações , Resultado do Tratamento , Adulto Jovem
6.
Artigo em Inglês | MEDLINE | ID: mdl-28264843

RESUMO

This study aimed to develop a prediction model to identify patients with candidemia who were at high risk of failing fluconazole treatment. Adult patients in the United States with candidemia who received fluconazole during hospitalization were selected from the Cerner Health Facts Hospital Database (04/2004 to 03/2013). Fluconazole failure was defined as switching/adding another antifungal, positive Candida culture ≥10 days after fluconazole initiation, or death during hospitalization. Patients were randomized into modeling and validation samples. Using the modeling sample, a regression analysis of least absolute shrinkage and selection operator was used to select risk predictors of fluconazole failure (demographics, Candida species, initiation of fluconazole before positive culture and after admission, and comorbidities, procedures, and treatments during the 6 months before admission and fluconazole initiation). The prediction model was evaluated using the validation sample. We found that of 987 identified patients (average age of 61 years, 51% male, 72% Caucasian), 49% failed and 51% did not fail fluconazole treatment. Of those who failed, 70% switched or added another antifungal, 21% had a second positive Candida test, and 42% died during hospitalization. Nine risk factors were included in the prediction model: days to start fluconazole after admission, Candida glabrata or Candida krusei infection, hematological malignancy, venous thromboembolism (VTE), enteral nutrition, use of nonoperative intubation/irrigation, and other antifungal use. All but VTE were associated with a higher risk of failure. The model's c-statistic was 0.65, with a Hosmer-Lemeshow test P value of 0.23. In summary, this prediction model identified patients with a high risk of fluconazole failure, illustrating the potential value and feasibility of personalizing candidemia treatment.


Assuntos
Antifúngicos/uso terapêutico , Candida/efeitos dos fármacos , Candidemia/tratamento farmacológico , Candidemia/mortalidade , Fluconazol/uso terapêutico , Farmacorresistência Fúngica , Feminino , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Modelos Teóricos , Fatores de Risco , Falha de Tratamento
7.
J Antimicrob Chemother ; 72(2): 462-466, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27798213

RESUMO

OBJECTIVES: Previously we demonstrated the benefit of isavuconazole in treating murine mucormycosis due to Rhizopus. We wanted to determine the efficacy of isavuconazole in treating murine mucormycosis caused by Mucor, the second most common cause of the disease. Furthermore, because we previously determined that Rhizopus possesses the target enzyme for echinocandins and micafungin has activity against murine mucormycosis, we compared the activity of combination therapy (isavuconazole + micafungin) with placebo, either drug alone or standard therapy of liposomal amphotericin B (LAmB) in treating pulmonary murine mucormycosis caused by Rhizopus delemar. METHODS: In vitro susceptibility to isavuconazole of Mucorales was evaluated using the CLSI M38-A2 method. Immunosuppressed mice were intratracheally infected with either Mucor circinelloides or R. delemar. Treatment with isavuconazole (orally), micafungin (intraperitoneally), a combination of both or LAmB (intravenously) was compared, with survival and tissue fungal burden serving as primary and secondary endpoints, respectively. RESULTS: Isavuconazole was as effective as LAmB in prolonging survival of mice infected with M. circinelloides. Against R. delemar-induced mucormycosis, all monotherapy treatments significantly improved survival of mice versus placebo without showing superiority over one another. However, LAmB was superior in lowering fungal burden in target organs. Although combination therapy of isavuconazole + micafungin did not enhance survival of mice over monotherapy, antagonism was not detected between the two drugs. CONCLUSION: Isavuconazole is effective in treating pulmonary murine mucormycosis due to Mucor. In addition, combination therapy of isavuconazole + micafungin does not demonstrate synergy and it is not antagonistic against Rhizopus-induced mucormycosis.


Assuntos
Antifúngicos/uso terapêutico , Equinocandinas/uso terapêutico , Lipopeptídeos/uso terapêutico , Mucor/efeitos dos fármacos , Mucormicose/tratamento farmacológico , Nitrilas/uso terapêutico , Piridinas/uso terapêutico , Rhizopus/efeitos dos fármacos , Triazóis/uso terapêutico , Animais , Quimioterapia Combinada , Pulmão/microbiologia , Masculino , Micafungina , Camundongos , Testes de Sensibilidade Microbiana
8.
Med Mycol ; 55(3): 269-277, 2017 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-27703022

RESUMO

Epidemiological characteristics of 333 proven and probable invasive mould infections (IMIs) among solid organ transplant recipients (SOTRs) identified between 2004 and 2008 from the Prospective Antifungal Therapy Alliance (PATH) registry are presented. Liver transplant recipients (LTRs) had the lowest median time to IMIs (109 days; interquartile range [IQR] 24-611 days), the highest rate of disseminated disease (n/N = 18/33; 55%), and highest mortality (n/N = 21/33; 64%). Lung transplant recipients had highest median time to IMIs (486 days; IQR 117-1358 days) and lowest mortality (n/N = 31/184; 17%). Complete or partial response at week 12 in patients with invasive aspergillosis (IA) was 67% (n/N = 189/281), and 41% (n/N = 9/22) in mucormycosis patients. In the composite outcome of death or no response to therapy, LTRs had the worst outcome. Higher suspicion of mold infection and institution of appropriate antifungal prophylactic strategies are warranted, especially in high risk LTRs.


Assuntos
Fungos/classificação , Fungos/isolamento & purificação , Infecções Fúngicas Invasivas/epidemiologia , Transplante de Órgãos/efeitos adversos , Transplantados , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antifúngicos/uso terapêutico , Quimioprevenção/métodos , Criança , Feminino , Humanos , Infecções Fúngicas Invasivas/microbiologia , Infecções Fúngicas Invasivas/mortalidade , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Análise de Sobrevida , Adulto Jovem
9.
Transpl Infect Dis ; 19(5)2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28722255

RESUMO

Patients undergoing treatment with immunosuppressant drugs following solid organ or hematopoietic stem cell transplantation are at particular risk for development of serious infections such as invasive aspergillosis. Four triazole antifungal drugs, voriconazole, posaconazole, itraconazole, and isavuconazole, are approved to treat invasive aspergillosis either as first- or second-line therapy. All of these agents are inhibitors of cytochrome P450 3A4, which plays a key role in metabolizing immunosuppressant drugs such as cyclosporine, tacrolimus, and sirolimus. Thus, co-administration of a triazole antifungal drug with these immunosuppressant drugs can potentially increase plasma concentrations of the immunosuppressant drugs, thereby resulting in toxicity, or upon discontinuation, inadvertently decrease the respective concentrations with increased risk of rejection or graft-versus-host disease. In this article, we review the evidence for the extent of inhibition of cytochrome P450 3A4 by each of these triazole antifungal drugs and assess their effects on cyclosporine, tacrolimus, and sirolimus. We also consider other factors affecting interactions of these two classes of drugs. Finally, we examine recommendations and strategies to evaluate and address those potential drug-drug interactions in these patients.


Assuntos
Antifúngicos/farmacocinética , Aspergilose/tratamento farmacológico , Sistema Enzimático do Citocromo P-450/metabolismo , Imunossupressores/farmacocinética , Antifúngicos/administração & dosagem , Antifúngicos/uso terapêutico , Interações Medicamentosas , Humanos , Imunossupressores/administração & dosagem
10.
Clin Infect Dis ; 63(3): 356-62, 2016 08 01.
Artigo em Inglês | MEDLINE | ID: mdl-27169478

RESUMO

BACKGROUND: Invasive fungal diseases (IFD) caused by Cryptococcus and dimorphic fungi are associated with significant morbidity and mortality. Isavuconazole (ISAV) is a novel, broad-spectrum, triazole antifungal agent (IV and by mouth [PO]) developed for the treatment of IFD. It displays potent activity in vitro against these pathogens and in this report we examine outcomes of patients with cryptococcosis or dimorphic fungal infections treated with ISAV. METHODS: The VITAL study was an open-label nonrandomized phase 3 trial conducted to evaluate the efficacy and safety of ISAV treatment in management of rare IFD. Patients received ISAV 200 mg 3 times daily for 2 days followed by 200 mg once-daily (IV or PO). Proven IFD and overall response at end of treatment (EOT) were determined by an independent, data-review committee. Mortality and safety were also assessed. RESULTS: Thirty-eight patients received ISAV for IFD caused by Cryptococcus spp. (n = 9), Paracoccidioides spp. (n = 10), Coccidioides spp. (n = 9), Histoplasma spp. (n = 7) and Blastomyces spp. (n = 3). The median length of therapy was 180 days (range 2-331 days). At EOT 24/38 (63%) patients exhibited a successful overall response. Furthermore, 8 of 38 (21%) had stable IFD at the end of therapy without progression of disease, and 6 (16%) patients had progressive IFD despite this antifungal therapy. Thirty-three (87%) patients experienced adverse events. CONCLUSIONS: ISAV was well tolerated and demonstrated clinical activity against these endemic fungi with a safety profile similar to that observed in larger studies, validating its broad-spectrum in vitro activity and suggesting it may be a valuable alternative to currently available agents. CLINICAL TRIALS REGISTRATION: NCT00634049.


Assuntos
Antifúngicos/farmacologia , Micoses/tratamento farmacológico , Nitrilas/farmacologia , Piridinas/farmacologia , Triazóis/farmacologia , Adulto , Idoso , Antifúngicos/efeitos adversos , Blastomicose/tratamento farmacológico , Blastomicose/microbiologia , Coccidioidomicose/tratamento farmacológico , Coccidioidomicose/microbiologia , Criptococose/tratamento farmacológico , Criptococose/microbiologia , Feminino , Histoplasmose/tratamento farmacológico , Histoplasmose/microbiologia , Humanos , Masculino , Pessoa de Meia-Idade , Micoses/microbiologia , Nitrilas/efeitos adversos , Paracoccidioidomicose/tratamento farmacológico , Paracoccidioidomicose/microbiologia , Piridinas/efeitos adversos , Triazóis/efeitos adversos , Adulto Jovem
11.
Antimicrob Agents Chemother ; 60(6): 3398-406, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-27001815

RESUMO

The majority of hospitalized patients receiving mold-active triazoles are at risk of drug-drug interactions (DDIs). Efforts are needed to increase awareness of DDIs that pose a serious risk of adverse events. Triazoles remain the most commonly utilized antifungals. Recent developments have included the mold-active triazoles (MATs) itraconazole, voriconazole, and posaconazole, which are first-line agents for the treatment of filamentous fungal infections but have the potential for DDIs. This objective of this study was to evaluate the prevalence of triazole DDIs. Hospitalized U.S. adults with MAT use were identified in the Cerner HealthFacts database, which contained data from over 150 hospitals (2005 to 2013). The severities of DDIs with MATs were categorized, using drug labels and the drug information from the Drugdex system (Thompson Micromedex), into four groups (contraindicated, major, moderate, and minor severity). DDIs of minor severity were not counted. A DDI event was considered to have occurred if the following two conditions were met: (i) the patient used at least one drug with a classification of at least a moderate interaction with the MAT during the hospitalization and (ii) there was a period of overlap between the administration of the MAT and that of the interacting drug of at least 1 day. A total of 6,962 hospitalizations with MAT use were identified. Among them, 88% of hospitalizations with voriconazole use, 86% of hospitalizations with itraconazole use, and 93% of hospitalizations with posaconazole use included the use of a concomitant interacting drug. A total of 68% of hospitalizations with posaconazole use, 34% of hospitalizations with itraconazole use, and 20% of hospitalizations with voriconazole use included the use of at least one drug with a DDI of contraindicated severity. A total of 83% of hospitalizations with posaconazole use, 61% of hospitalizations with itraconazole use, and 82% of hospitalizations with voriconazole use included the use of at least one drug that resulted in a severe DDI. The findings of this study demonstrate that a majority of hospitalized patients receiving MAT are at risk for severe drug-drug interactions and highlight the need for antifungal stewardship.


Assuntos
Antifúngicos/farmacologia , Interações Medicamentosas , Triazóis/farmacologia , Hospitalização , Humanos , Itraconazol/farmacologia , Testes de Sensibilidade Microbiana , Voriconazol/farmacologia
12.
BMC Infect Dis ; 16(1): 730, 2016 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-27905900

RESUMO

BACKGROUND: Mucormycosis is a rare but devastating fungal infection primarily affecting immunocompromised patients such as those with hematological malignancy, bone marrow and solid organ transplantation, and patients with diabetes, and, even more rarely, immunocompetent patients. The objective of this study was to assess the prevalence and burden, both clinical and economic, of mucormycosis among hospitalized patients in the U.S. METHODS: This is a retrospective study using the Premier PerspectiveTM Comparative Database, with more than 560 participating hospitals covering 104 million patients (January 2005-June 2014). All hospitalizations in the database were evaluated for the presence of mucormycosis using either an ICD-9 code of 117.7 or a positive laboratory result for Mucorales. Hospitalizations were further required to have prescriptions of amphotericin B or posaconazole to be considered as mucormycosis-related hospitalizations. The prevalence of mucormycosis-related hospitalizations among all hospital discharges was estimated. Mortality rate at discharge, length of hospital stay, and readmission rates at 1 and 3 months were evaluated among mucormycosis-related hospitalizations. Cost per hospital stay and average per diem cost (inflated to 2014 USD) were reported. RESULTS: The prevalence of mucormycosis-related hospitalizations was estimated as 0.12 per 10,000 discharges during January 2005-June 2014. It increased to 0.16 per 10,000 discharges if the definition of mucormycosis was relaxed to not require the use of amphotericin B or posaconazole. The median length of stay was 17 days, with 23% dead at discharge; readmission rates were high, with 30 and 37% of patients readmitted within one and three months of discharge, respectively. The average cost per hospital stay was $112,419, and the average per diem cost was $4,096. CONCLUSIONS: The study provides a recent estimate of the prevalence and burden of mucormycosis among hospitalized patients. The high clinical and economic burden associated with mucormycosis highlights the importance of establishing active surveillance and optimizing prophylactic and active treatment in susceptible patients.


Assuntos
Efeitos Psicossociais da Doença , Hospitalização/estatística & dados numéricos , Mucormicose/epidemiologia , Adolescente , Adulto , Idoso , Antifúngicos/economia , Antifúngicos/uso terapêutico , Criança , Bases de Dados Factuais , Feminino , Custos Hospitalares/estatística & dados numéricos , Hospitalização/economia , Humanos , Tempo de Internação/economia , Masculino , Pessoa de Meia-Idade , Mucormicose/economia , Mucormicose/terapia , Prevalência , Estudos Retrospectivos , Estados Unidos/epidemiologia , Adulto Jovem
13.
Clin Infect Dis ; 61 Suppl 6: S601-3, 2015 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-26567276

RESUMO

Echinocandins are N-acyl-substituted cyclic hexapeptides with potent in vitro and in vivo activity against Candida species that are used for primary treatment and prevention of candidemia and invasive candidiasis. Recent progress in the translational research of echinocandins has led to new approaches for treatment of central venous catheter Candida biofilms. Other studies have laid the experimental and clinical foundation for use of extended dosing intervals for administration of echinocandins in treatment and prevention of candidemia and invasive candidiasis.


Assuntos
Antifúngicos/uso terapêutico , Candida/efeitos dos fármacos , Candidíase/tratamento farmacológico , Equinocandinas/uso terapêutico , Biofilmes/efeitos dos fármacos , Candida/fisiologia , Candidemia/tratamento farmacológico , Candidemia/prevenção & controle , Candidíase/microbiologia , Candidíase/prevenção & controle , Candidíase Invasiva/tratamento farmacológico , Candidíase Invasiva/prevenção & controle , Caspofungina , Infecções Relacionadas a Cateter/tratamento farmacológico , Equinocandinas/química , Humanos , Lipopeptídeos/uso terapêutico , Micafungina , Pesquisa Translacional Biomédica
14.
Antimicrob Agents Chemother ; 59(2): 905-13, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25421470

RESUMO

The aim of this analysis was to identify therapeutic micafungin regimens for children that produce the same micafungin exposures known to be effective for the prevention and treatment of Candida infections in adults. Pediatric pharmacokinetic data from 229 patients between the ages of 4 months and <17 years were obtained from four phase I and two phase III clinical trials. Population pharmacokinetic models were used to simulate the proportion of children who had a steady-state area under the concentration-time curve at 24 hours (AUC24) of micafungin within the 10th to 90th percentile range observed in a population of adults receiving a dose of micafungin with established efficacy for invasive candidiasis (100 mg/day), i.e., 75 to 139 µg·h/ml. Simulated pediatric dosages of 0.5 to 5 mg/kg of body weight/day were explored. A two-compartment model was used that incorporated body weight as a predefined covariate for allometric scaling of the pharmacokinetic parameters. During construction of the model, aspartate aminotransferase and total bilirubin were also identified as covariates that had a significant effect on micafungin clearance. A dose of 2 mg/kg resulted in the highest proportion of children within the predefined micafungin AUC24 target range for invasive candidiasis. Cutoffs of 40 or 50 kg for weight-based dosing resulted in heavier children being appropriately dosed. Thus, dose regimens of 1, 2, and 3 mg/kg/day micafungin are appropriate for the prevention of invasive candidiasis, the treatment of invasive candidiasis, and the treatment of esophageal candidiasis, respectively, in children aged 4 months to <17 years.


Assuntos
Antifúngicos/farmacocinética , Equinocandinas/farmacocinética , Lipopeptídeos/farmacocinética , Adolescente , Candidíase/tratamento farmacológico , Candidíase/prevenção & controle , Candidíase Invasiva/tratamento farmacológico , Candidíase Invasiva/prevenção & controle , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Micafungina
15.
J Pediatr Hematol Oncol ; 37(1): e45-50, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25072363

RESUMO

Micafungin is a potent echinocandin antifungal that can be used for both prophylaxis and treatment of Candida infections. This open-label study assessed the pharmacokinetics and safety profile of prophylactic micafungin in children and adolescents (aged 4 mo to 16 y) undergoing hematopoietic stem cell transplantation. Patients received once-daily doses of either 1 or 1.5 mg/kg micafungin, based on their body weight, for 10 to 14 days. In total, 40 patients received micafungin. Area under the plasma micafungin concentration-time curve was highest in patients aged 6 to 11 years in the 1.5 mg/kg treatment group. Peak plasma micafungin concentration displayed no age-related differences, but was higher in the 1.5 mg/kg versus the 1 mg/kg group. Clearance at steady state by weight and volume of distribution by weight were considerably higher in patients aged 4 months to 5 years. Results from this study show that age and body weight affect micafungin pharmacokinetics in pediatric patients undergoing hematopoietic stem cell transplantation.


Assuntos
Antifúngicos/farmacocinética , Equinocandinas/farmacocinética , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Lipopeptídeos/farmacocinética , Micoses/prevenção & controle , Adolescente , Criança , Pré-Escolar , Equinocandinas/efeitos adversos , Feminino , Humanos , Lipopeptídeos/efeitos adversos , Masculino , Micafungina
16.
Mycoses ; 57(4): 240-6, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24147728

RESUMO

Mucormycosis is increasingly encountered in immunosuppressed patients, such as those with haematological malignancies or stem cell transplantation. We present a descriptive analysis of 121 cases of mucormycosis from the Prospective Antifungal Therapy Alliance(®) registry (July 2004 to December 2008). Patients with proven or probable mucormycosis were enrolled and followed prospectively for 12 weeks. The most common underlying disease and site of infection were haematologic malignancy (61.2%) and lungs (46.3%) respectively. Rhizopus (n = 63; 52.1%) was the most commonly isolated species, followed by Mucor (n = 28; 23.1%), other or unknown (n = 17; 14.0%), Rhizomucor (n = 9; 7.4%) and Lichtheimia (n = 4; 3.3%). The 12-week Kaplan-Meier survival probability for all patients was 0.41; however, there was large variation in survival probabilities between species, with highest survival probability observed for Lichtheimia (0.5), followed by Rhizopus (0.47), Mucor (0.40), unknown Mucormycetes species (0.40), other Mucormycetes species (0.17) and Rhizomucor (0.15). Prior use of voriconazole decreased 12-week survival probability. Survival probability was higher in patients receiving amphotericin B by Day 3 (0.72) vs. those who started amphotericin B therapy after Day 3 (0.33). The low survival probability observed underscores the importance of further studies of mucormycosis. Optimal treatment selection and timing may improve prognosis.


Assuntos
Antifúngicos/uso terapêutico , Mucorales/isolamento & purificação , Mucormicose/tratamento farmacológico , Mucormicose/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mucorales/classificação , Mucormicose/microbiologia , Mucormicose/mortalidade , Neoplasias/complicações , Análise de Sobrevida
17.
Mycoses ; 57(11): 652-8, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24943384

RESUMO

Invasive Fusarium infections occur in immunosuppressed patients, especially those with haematological malignancies. We conducted a descriptive analysis of data from patients with invasive fusariosis identified in the Prospective Antifungal Therapy Alliance registry, which collected data on invasive fungal infections in the United States and Canada from 2004 to 2008. In this series of 65 patients with proven (83.1%) and probable (16.9%) invasive fusariosis, the most common underlying condition was haematological malignancy, in which neutropenia and corticosteroid usage frequently occurred. Seven patients with invasive Fusarium infections had cross-reactive galactomannan assay results. The survival rate for all patients at 90 days was 44%, which was an improvement compared with historical data. Disseminated disease occurred frequently (35.4%), and patients with and without disseminated disease had survival rates of 33% and 50%, respectively. Posaconazole and voriconazole were the most frequently employed therapies and may be linked to the improved survival rate observed in this patient series. In summary, patients with invasive Fusarium infections continue to have high fatality rates, especially those with disseminated disease. Fusarium infections should be strongly considered in the absence of Aspergillus isolation in patients at high risk of mould infections with positive galactomannan assay test results.


Assuntos
Antifúngicos/uso terapêutico , Fusariose/tratamento farmacológico , Fusarium/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Canadá/epidemiologia , Feminino , Fusariose/epidemiologia , Fusariose/microbiologia , Fusariose/mortalidade , Fusarium/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Sistema de Registros , Análise de Sobrevida , Resultado do Tratamento , Triazóis/uso terapêutico , Estados Unidos/epidemiologia , Voriconazol/uso terapêutico , Adulto Jovem
18.
Can J Infect Dis Med Microbiol ; 25(1): 17-23, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24634683

RESUMO

BACKGROUND: The Prospective Antifungal Therapy Alliance(®) registry is a prospective surveillance study that collected data on the diagnosis, management and outcomes of invasive fungal infections (IFIs) from 25 centres in North America from 2004 to 2008. OBJECTIVE: To evaluate surveillance data on IFIs obtained from study centres located in Canada. METHODS: Patients with proven or probable IFIs at two Canadian medical centres were enrolled in the registry. Information regarding patient demographics, fungal species, infection sites, diagnosis techniques, therapy and survival were analyzed. RESULTS: A total of 347 patients from Canada with documented IFIs were enrolled in the Prospective Antifungal Therapy Alliance registry. Infections occurred most commonly in general medicine (71.8%), nontransplant surgery (32.6%) and patients with hematological malignancies (21.0%). There were 287 proven IFIs, including 248 Candida infections. Forty-six patients had invasive aspergillosis (IA); all of these were probable infections. Most cases of invasive candidiasis were confirmed using blood culture (90.5%), while IA was most frequently diagnosed using computed tomography scan (82.6%) and serological methods (82.6%). Fluconazole was the most common therapy used for Candida infections, followed by the echinocandins. Voriconazole therapy was most commonly prescribed for IA. CONCLUSIONS: The present study demonstrated that general medicine, surgery and hematological malignancy patients in Canada are susceptible to developing IFIs. In contrast to the United States, Candida albicans remains responsible for most IFIs in these Canadian centres. Surrogate serum markers are commonly being used for the diagnosis of IA, while therapy for both IFIs has shifted to broader-spectrum azoles and echinocandins.


HISTORIQUE: Le registre PATH de la Prospective Antifungal Therapy Alliance est une étude de surveillance prospective qui a permis de colliger des données sur le diagnostic, la prise en charge et les issues des infections fongiques invasives (IFI) provenant de 25 centres d'Amérique du Nord entre 2004 et 2008. OBJECTIF: Évaluer les données de surveillance sur les IFI provenant de centres d'études situés au Canada. MÉTHODOLOGIE: Les patients ayant une IFI démontrée ou probable provenant de deux centres médicaux canadiens ont été inscrits au registre. Les chercheurs ont analysé l'information portant sur la démographie des patients, les espèces fongiques, les foyers d'infection, les techniques diagnostiques, la thérapie et la survie. RÉSULTATS: Au total, 347 patients du Canada ayant une IFI vérifiée ont été inscrits au registre PATH. Les infections se produisaient surtout en médecine générale (71,8 %), en chirurgie pour autre chose que des transplantations (32,6 %) et chez les patients ayant une tumeur hématologique maligne (21,0 %). Ainsi, 287 IFI ont été démontrées, y compris 248 infections à Candida. Quarante-six patients avaient une aspergillose invasive (AI), qui étaient toutes des infections probables. La plupart des candidoses invasives ont été confirmées par des prélèvements sanguins (90,5 %), tandis que les AI étaient surtout diagnostiquées par tomodensitométrie (82,6 %) et méthodes sérologiques (82,6 %). Le fluconazole était le traitement le plus utilisé pour traiter les infections à Candida, suivi des échinocandines. Quant au traitement au voriconazole, c'était le plus prescrit pour l'AI. CONCLUSIONS: La présente étude a démontré qu'au Canada, les patients en médecine générale, en chirurgie et ayant une tumeur hématologique maligne sont susceptibles de contracter une IFI. Contrairement aux États-Unis, le Candida albicans demeure responsable de la plupart des IFI dans ces centres canadiens. Des marqueurs sériques de remplacement sont souvent utilisés pour diagnostiquer l'AI, tandis que le traitement des deux IFI est désormais assuré par des aux azoles et des échinocandines à large spectre.

19.
J Womens Health (Larchmt) ; 32(2): 178-186, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-36255448

RESUMO

Background: Ibrexafungerp is a novel antifungal treatment for acute vulvovaginal candidiasis (VVC). Using pooled data from two phase three studies (VANISH 303 and 306) in the treatment of acute VVC, this analysis sought to determine the effectiveness of ibrexafungerp in various patient subgroups that may impact outcomes. Materials and Methods: Data from VANISH 303 (NCT03734991) and VANISH 306 (NCT03987620) evaluating ibrexafungerp 300 mg twice daily (BID) for 1 day versus placebo, were pooled and analyzed to determine clinical cure rate, clinical improvement, and mycological cure at the test-of-cure visit (day 11 ± 3) and symptom resolution at the follow-up visit (day 25 ± 4) in the overall population. Patient subgroups analyzed included race, body mass index (BMI), baseline vulvovaginal signs and symptoms (VSS) score, and Candida species. Results: At the test-of-cure visit, patients receiving ibrexafungerp, compared with those who received placebo, had significantly higher rates of clinical cure (56.9% [214/376 patients] vs. 35.7% [65/182 patients]), clinical improvement (68.4% [257/376 patients] vs. 45.1% [82/182 patients]), and mycological cure (54.0% [203/376 patients] vs. 24.2% [44/182 patients]; all p < 0.0001). At the follow-up visit, patients receiving ibrexafungerp had sustained responses with higher symptom resolution rates (66.8% [251/376 patients]) versus placebo (48.4% [88/182 patients]; p < 0.0001). Race, BMI, baseline VSS score (including VSS severity score 13-18), and Candida species infection did not adversely affect clinical cure rates. Safety analysis results were consistent with the individual studies. Conclusions: Ibrexafungerp provides a safe and well-tolerated first-in-class fungicidal, 1-day oral treatment for patients with acute VVC, the first new therapy in >20 years. Clinical Trial Registration Number: NCT03734991.


Assuntos
Candidíase Vulvovaginal , Feminino , Humanos , Antifúngicos/uso terapêutico , Candidíase Vulvovaginal/tratamento farmacológico , Fluconazol/efeitos adversos , Glicosídeos/uso terapêutico
20.
J Fungi (Basel) ; 8(11)2022 Oct 25.
Artigo em Inglês | MEDLINE | ID: mdl-36354888

RESUMO

Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies. This combination of weakened-host defense, with limited antifungal treatment options, and the opportunism of environmental molds renders patients at risk and especially vulnerable to invasive mold infections such as Aspergillus and members of the Order Mucorales. Currently, available antifungal drugs such as azoles and echinocandins, as well as combinations of the same, offer some degree of efficacy in the prevention and treatment of invasive mold infections, but their use is often limited by drug resistance mechanisms, toxicity, drug-drug interactions, and the relative paucity of oral treatment options. Clearly, there is a need for agents that are of a new class that provides adequate tissue penetration, can be administered orally, and have broad-spectrum efficacy against fungal infections, including those caused by invasive mold organisms. Ibrexafungerp, an orally bioavailable glucan synthase inhibitor, is the first in a new class of triterpenoid antifungals and shares a similar target to the well-established echinocandins. Ibrexafungerp has a very favorable pharmacokinetic profile for the treatment of fungal infections with excellent tissue penetration in organs targeted by molds, such as the lungs, liver, and skin. Ibrexafungerp has demonstrated in vitro activity against Aspergillus spp. as well as efficacy in animal models of invasive aspergillosis and mucormycosis. Furthermore, ibrexafungerp is approved for use in the USA for the treatment of women with vulvovaginal candidiasis. Ibrexafungerp is currently being evaluated in clinical trials as monotherapy or in combination with other antifungals for treating invasive fungal infections caused by yeasts and molds. Thus, ibrexafungerp offers promise as a new addition to the clinician's armamentarium against these difficult-to-treat infections.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA